
Corporate profile
Grünenthal is a global leader in pain management and related diseases.
We have a long track record of bringing innovative treatments to patients worldwide. As a fully integrated pharmaceutical company, we cover the entire value chain – from drug research and development to commercialisation of portfolios with growth products and established medicines. We operate in accordance with the highest ethical and regulatory standards. At Grünenthal, we focus our efforts on our vision of a World Free of Pain.
employees worldwide
billion euros in 2023
countries across Europe, Latin America, and the US
countries
R&D sites – one R&D Unit in Aachen (Germany) and an Innovation Hub in Boston, (USA)
manufacturing sites in Europe and Latin America

Our unique commitment
For over 50 years, we have been a pioneer in pain treatments, tackling critical unmet medical needs and bringing us closer to our vision of a World Free of Pain.

ESG Industry Leader
At Grünenthal, conducting our business responsibly is an integral part of our company’s strategy and culture. We aspire to create a positive impact for society – in our core business and beyond. We are guided by integrity, transparency and the highest ethical standards. Our industry-leading way of doing business responsibly is reflected in our external Environment, Social and Governance (ESG) ratings.

Global capabilities
Grünenthal operates five world-class manufacturing sites around the globe, where we produce all of our own products, as well as manufacturing medicines for key industry partners. We have made significant investments into our facilities and are fully committed to ensuring the quality, safety and sustainability of every medicine we produce for patients.

Pipeline
Our scientists have developed several life-changing pain medicines for patients. To move closer to our vision of a World Free of Pain, we are pursuing a range of programs across different modalities, targets, and mechanisms of action.